Eton Pharmaceuticals, Inc.
Key Metrics
- Previous Close
- $61.48
- 52-Week Range
- $14.27 – $63.83
- Market Cap
- $1.71B
- P/E (TTM)
- 153.62
- EPS (TTM)
- 0.39
- Dividend Yield
- —
Advanced Metrics
- Price/Book
- 36.38
- PEG Ratio
- —
- Return on Equity
- 35.97%
- Return on Assets
- 11.86%
- Gross Margin
- 61.41%
- Operating Margin
- 35.77%
- Profit Margin
- 12.02%
- Current Ratio
- 1.52
- Debt/Equity
- 0.63
- Total Debt
- $29.23M
- Free Cash Flow
- $6.58M
- Revenue Growth
- 98.60%
- Earnings Growth
- —
- Enterprise Value
- $1.76B
Market Snapshot
About
Eton Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare diseases. The company's portfolio includes products targeting conditions with significant unmet medical needs, including rare pediatric disorders and metabolic diseases. Eton employs a strategy of in-licensing and developing products that have been previously approved or are in late-stage development, reducing clinical risk. The company's business model focuses on niche therapeutic areas where it can achieve meaningful market share with smaller patient populations.